Pune, Maharashtra, India, December 3 2020 (Wiredrelease) Allied Analytics –:UPDATE AVAILABLE ON-DEMAND
The report on the global cholera vaccine market highlights that the market is expected to reach $65 million in 2017, and is projected to reach $207 million by 2025, growing at a CAGR of 15.6% from 2018 to 2025. The report offers the current market size and forecasts along with Porter’s Five Forces analysis to help market players, stakeholders, startups, and investors to determine the current scenario and take further steps for the future. Drivers and opportunities for highest revenue generating and fastest growing segments would help in tapping into specific segment to achieve growth. Moreover, regional analysis would assist in expansion strategies for the market players and startups. The Dukoral segment accounted around half of the total market share in 2017.
Cholera is an acute, profusely watery diarrhea caused by Vibrio cholera and spreads through contamination of water and food. In addition, it is closely associated with poor sanitation and lack of clean drinking water. The number of global cholera disease cases accounts for around 35 million every year. Currently, the frequency of cholera epidemics has increased mainly in low- and middle-income countries. Cholera control is the main priority in cholera-endemic areas, which in turn increase the demand for the cholera vaccines.
Click Here To Access Free Sample Report @ https://www.alliedmarketresearch.com/request-sample/5177
The cholera vaccine market is expected to exhibit significant growth during the forecast period due to lack of proper sanitation & consumption of contaminated food and growth in awareness about cholera preventive care. In addition, development of novel approaches for new cholera vaccine further drive the market growth. However, risk of adverse effects and the time taken for the regulatory approval is projected to impede the market growth. On the contrary, high growth opportunities in untapped markets are expected to offer significant profitable opportunities for the market players in the near future.
The cholera vaccine report offers an in-depth analysis of the Covid-19 impact on various market segments and countries. Moreover, the report offers major market trends and forecasts, considering the Covid-19 situation.
Based on end user, the market is categorized into hospitals & clinics, research & academic laboratories, and others. The hospitals & clinics segment presently dominates the market, and is expected to remain dominant during the forecast period. This is attributed to the fact that hospitals and clinics are authorized to organize campaigns for cholera vaccination, as the number of cases for cholera diseases is rapidly growing in LMICs.
Inquire before buying @ https://www.alliedmarketresearch.com/purchase-enquiry/5177
Asia-Pacific was the leading revenue contributor to the global cholera vaccine market in 2017, and is expected to remain dominant throughout the forecast period due to increase in the prevalence of cholera disease and rise in importance of immunization. However, North America is expected to grow at the highest CAGR during the study period. This is attributed to the launch of the first and only oral cholera vaccine, Vaxchora, in the USA. Furthermore, the number of travelers to the cholera-affected countries is increasing, which in turn increases the demand for immunization.
The Major Key Players Are:
Valneva SE, Emergent BioSolutions, Inc. (PaxVax, Inc.), Astellas Pharma, Inc., Sanofi (Shantha Biotechnics Private Limited), Eubiologics Co., Ltd., and Johnson & Johnson (Crucell), Celldex Therapeutics, Inc.
Access Full Report @ https://www.alliedmarketresearch.com/cholera-vaccine-market
The other Key players are:
Merck & Co., Inc., GlaxoSmithKline plc., and others.
Key Findings Of The Study:
• Based on product, the Vaxchora segment is expected to experience rapid growth in the market, and is projected to grow at a CAGR of 17.4% from 2018 to 2025.
• Depending on end user, the pharmaceutical & biotechnology companies segment is expected to exhibit the highest CAGR during the forecast period.
• U.S. generated the highest revenue in the global cholera vaccine market industry in 2017, accounting less than one-tenth of the global market in 2017.
• North America is estimated to grow at a CAGR of 17.1% during the forecast period.
Similar Reports:
Global Portable Ventilators Market
About Us:
Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com
This content has been published by Allied Analytics company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at contact@wiredrelease.com.
source https://wiredrelease.com/press-release/cholera-vaccine-market-value-to-grasp-207-million-by-2025-registering-cagr-of-15-6-2020-12-02
No comments:
Post a Comment